Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COCOS: Cediranib and Olaparib vs chemotherapy in platinum-resistant/refractory ovarian cancer
jRCT2031190097Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Mar 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial of cediranib, olaparib, paclitaxel, doxorubicin and topotecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (3 arms), sponsored by NRG Oncology. Primary endpoints: Overall survival and Progression-free survival. Started Mar 2020; status: active, not recruiting.
02
Drugs
cediranibolaparibpaclitaxeldoxorubicintopotecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on jRCT2031190097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190097.